The singer, 50, revealed earlier this year that his mother Janet had been diagnosed with dementia, four-years after his ...
BIIB122, previously known as DNL151, is a small molecule designed to inhibit LRRK2, mutations in which are the most common cause of inherited Parkinson's.
Exidavnemab is being developed as a potential disease-modifying treatment, aiming to halt or slow the progression of ...
There is growing evidence that immune-positron emission tomography (immuno-PET) can provide a real-time quantitative readout ...
The new Marie Skłodowska-Curie Doctoral Network AIPD is dedicated to investigating artificial intelligence methods to combat Parkinson's disease. It ...
Cadonilimab plus chemotherapy significantly improved progression-free survival in patients with persistent, recurrent, or ...
SOUTH SAN FRANCISCO, CA, USA I 05, 2024 I Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical ...
STOCKHOLM, Sweden I 5, 2024 I BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient has been dosed with exidavnemab ...
The 5-a-side match, which was held at the Eagle Club, Surulere, Lagos last weekend was in collaboration with Parkinson’s ...